BlossomHill Therapeutics Closes $100 Million Series B Financing

SAN DIEGO, Calif.–(BUSINESS WIRE)–BlossomHill Therapeutics, Inc., a biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today announced the closing of a $100 million Series B financing round. The round was led by Colt Ventures with participation from new and existing…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks